We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.
An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)
References
1
1Kand, P, Basu, S. Clinicoradiological characteristics of patients with differentiated thyroid carcinoma and renal metastasis: case series with follow up. J Laryngol Otol2014;128:203–8Google Scholar
3Stokkel, MPM, Duchateau, CSJ, Dragoiescu, C. The value of FDG-PET in the follow-up of differentiated thyroid cancer: a review of the literature. Q J Nucl Med Mol Imaging2006;50:78–87Google Scholar
4
4Heston, TF, Wahl, RL. Molecular imaging in thyroid cancer. Cancer Imaging2010;10:1–7Google Scholar
5
5Ong, SC, Ng, DCE, Sundram, FX. Initial experience in use of fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography in thyroid carcinoma patients with elevated serum thyroglobulin but negative iodine-131 whole body scans. Singapore Med J2005;46:297–301Google ScholarPubMed
6
6Ma, C, Kuang, A, Xie, J, Ma, T. Possible explanations for patients with discordant findings of serum thyroglobulin and 131I whole-body scanning. J Nucl Med2005;46:1473–80Google Scholar